Note: This story was updated May 6, 2024, to correct that Cullinan Therapeutics continues to pursue its oncology platform while also expanding into treatments for autoimmune diseases including lupus. Cullinan Therapeutics has announced its plans to exclusively pursue the development of its T-cell-engager CLN-978 as a treatment for…
For this Lupus Awareness Month, marked each May, the focus is on educating people about the autoimmune disorder thought to affect about 1.5 million U.S. residents and more than 5 million individuals globally. World Lupus Day, bringing disease warriors worldwide together, will be observed on May…
The first patient has been dosed in the U.S. as part of a clinical trial testing AlloNK, an experimental natural killer (NK) cell therapy candidate, in patients with lupus nephritis, one of the most common and severe complications of lupus. The open-label Phase 1 trial (NCT06265220) is…
The U.S. Food and Drug Administration’s (FDA) Center for Biologics Evaluation and Research (CBER) is joining the Lupus Accelerating Breakthroughs Consortium (Lupus ABC) to focus on CAR T-cell treatments and other engineered cell therapies, a promising new therapeutic field now being explored for lupus. “We are delighted to have…
Depression is highly prevalent among people with systemic lupus erythematosus (SLE), but often goes undiagnosed, according to a single center study in Pakistan. The “treatment of depression is a vital component in the management of these patients and should be offered where appropriate,” the researchers wrote in “…
The U.S. Food and Drug Administration (FDA) has cleared a clinical trial to evaluate the safety and preliminary effectiveness of CB-010, Caribou Biosciences’ investigational CAR T-cell therapy, for lupus that affects the kidneys and other organs. The multicenter Phase 1 trial, dubbed GALLOP, should begin by the end…
Treatment with the investigational injection therapy itolizumab significantly reduced urine protein levels, a marker of kidney dysfunction, in people with active lupus nephritis, a serious lupus complication marked by kidney damage and inflammation. That’s according to top-line results from a Phase 1b trial called EQUALISE (NCT04128579) that were…
Ampel BioSolutions is launching LuGENE, a blood test that uses artificial intelligence (AI) to look at a patient’s gene activity and predict when lupus flares are likely to happen and which medications could be most effective to keep symptoms in check. LuGENE is currently available through the company-sponsored…
FibroBiologics, a biopharmaceutical company that seeks to develop and commercialize fibroblast cell-based therapies, has filed an application with the United States Patent and Trademark Office covering the use of its technology to potentially treat lupus. Using its proprietary fibroblast platform, the Houston-based company aims to develop cures…
The U.S. Food and Drug Administration (FDA) has approved a clinical trial to evaluate the safety and effectiveness of Synthekine‘s two-component immunotherapy for the treatment of certain patients with lupus, without using lymphodepletion, a process in which chemotherapy is used beforehand to eliminate disease-causing immune cells. The multicenter, dose…